aBETting therapeutic resistance by Wnt Signaling

BET inhibition has emerged as a promising epigenetic therapy for malignancies in the last five years, but little consensus has developed regarding what may mediate the axis between sensitivity and resistance. Two recent papers published in Na- ture attempt to address this question in acute myeloid l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell research 2015-11, Vol.25 (11), p.1187-1188
Hauptverfasser:	Engelke, Carl G, Chinnaiyan, Arul M
Format:	Artikel
Sprache:	eng
Schlagworte:	631/80/86 692/699/67/1059/2326 692/699/67/1990/283/1897 AML Animals Azepines - antagonists & inhibitors Biomarkers, Tumor Biomedical and Life Sciences Cell Biology Drug Resistance - physiology Leukemia Life Sciences Mice Models, Animal Neoplasms - therapy Research Highlight Triazoles - antagonists & inhibitors Wnt Proteins - antagonists & inhibitors Wnt Signaling Pathway - drug effects Wnt信号通路敏感性治疗性生物标志物自主确定表观遗传论文发表
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BET inhibition has emerged as a promising epigenetic therapy for malignancies in the last five years, but little consensus has developed regarding what may mediate the axis between sensitivity and resistance. Two recent papers published in Na- ture attempt to address this question in acute myeloid leukemia （AML） and independently identify the Wnt signaling pathway as a driver and biomarker of therapeutic resistance.
ISSN:	1001-0602 1748-7838
DOI:	10.1038/cr.2015.127